Blue Pharmacy: Marine Biodiversity as a Sustainable Source of Novel Therapeutics

Abstract

Blue pharmacy represents a rapidly expanding frontier in drug discovery, emphasizing the exploration of marine biodiversity for novel bioactive compounds with pharmaceutical relevance. Marine ecosystems harbor unparalleled biological and chemical diversity, shaped by extreme environmental pressures that drive the evolution of unique secondary metabolites. Marine microorganisms, algae, invertebrates, and their symbiotic associations have emerged as prolific producers of structurally diverse compounds exhibiting anticancer, antimicrobial, antiviral, anti-inflammatory, and neuroprotective activities. Marine microorganisms are increasingly recognized as major producers of bioactive metabolites, offering scalable and renewable drug leads. Advances in omics technologies, genome mining, and synthetic biology have significantly accelerated the identification and characterization of marine natural products, overcoming traditional cultivation and supply limitations. Several marine-derived compounds have successfully transitioned into clinical use, including anticancer and analgesic drugs, highlighting the translational potential of blue pharmacy. However, challenges related to sustainable harvesting, ecological conservation, and regulatory pathways remain critical considerations. This review synthesizes recent developments in marine-derived drug discovery, therapeutic applications, sustainability strategies, and alignment with global health and Sustainable Development Goals (SDGs). Blue pharmacy is positioned as a key contributor to future pharmaceutical innovation, addressing antimicrobial resistance, chronic diseases, and unmet medical needs through environmentally responsible approaches.